Valuation: Precision Therapeutics Inc

Market Cap 9.27Cr 8.3Cr 7.64Cr 6.92Cr 13Cr 880.47Cr 13Cr 91Cr 37Cr 463.15Cr 35Cr 34Cr 1.46TCr P/E 2026 *
-4.6x
P/E 2027 * -72.7x
Enterprise Value 9.27Cr 8.3Cr 7.64Cr 6.92Cr 13Cr 880.47Cr 13Cr 91Cr 37Cr 463.15Cr 35Cr 34Cr 1.46TCr EV / Sales 2026 *
1.54x
EV / Sales 2027 * 0.21x
Free-Float
93.93%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 09/02/2026
Director of Finance/CFO - 16/04/2026
President - 01/04/2026
Director TitleAgeSince
Director/Board Member 66 19/02/2020
Chairman 78 09/02/2026
Director/Board Member 60 09/07/2020
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 9.27Cr
-0.62%-1.87%+46.31%+56.99% 6.38TCr
+0.35%+3.20%+14.92%+84.55% 5.64TCr
+0.53%+1.96%+15.37%+106.81% 5.46TCr
-2.81%-4.31%+23.50%+50.90% 4.41TCr
-0.33%-1.93%+20.15%+98.45% 4.21TCr
+0.55%+2.31%+224.97%+942.56% 4.1TCr
+3.27%+47.96%+112.67%+96.48% 3.49TCr
+1.22%-1.44%+14.89%+47.15% 3.28TCr
+0.89%+20.55%-42.03%+373.03% 2.47TCr
Average -0.45%+7.54%+47.86%+206.32% 4.38TCr
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2026 *2027 *
Net sales 6.04Cr 5.41Cr 4.98Cr 4.51Cr 8.43Cr 573.5Cr 8.59Cr 59Cr 24Cr 301.68Cr 23Cr 22Cr 951.38Cr 43Cr 39Cr 36Cr 32Cr 60Cr 4.1TCr 61Cr 423.71Cr 170.09Cr 2.15TCr 161.86Cr 158.42Cr 6.79TCr
Net income -4.14Cr -3.71Cr -3.41Cr -3.09Cr -5.78Cr -393.1Cr -5.88Cr -41Cr -16Cr -206.78Cr -16Cr -15Cr -652.11Cr -45L -40.3L -37.07L -33.59L -62.79L -43Cr -63.96L -4.42Cr -1.77Cr -22Cr -1.69Cr -1.65Cr -71Cr
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-